Ferrous Fumarate

Summary

Ferrous Fumarate (CHEMBL1200640) is an approved small molecule (ATC B03AA02); indicated across 5 conditions including iron deficiency anemia and anemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B03AA02
• Indications: 5 conditions
• Clinical trials: 33

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200640
Name	Ferrous Fumarate
Type	Small molecule
Max phase	4
ATC	B03AA02

Also known as: Cpiron, Erco-fer, Ercoferro, Ferrofume, Ferrosi fumaras, Ferrous fumarate, Fersaday, Fersamal, Galfer, Heferol, Hemoton, Ircon

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
iron deficiency anemia	4	MONDO:0001356	HP:0001891
anemia	4	MONDO:0002280	EFO:0004272
HIV infectious disease	1	MONDO:0005109	EFO:0000764
Helicobacter pylori infectious disease	1	MONDO:0006781	EFO:1000961

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 33.

Phase distribution

Phase	Trials
Not specified	14
PHASE4	9
PHASE3	5
PHASE2	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01078818	PHASE4	COMPLETED	Oral and Intravenous Iron in Patients Postoperative Cardiovascular Surgery Under Extracorporeal Circulation
NCT01953107	PHASE4	COMPLETED	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
NCT01975272	PHASE4	TERMINATED	The Use of Iron Therapy for Patients With Anemia After Caesarean Section
NCT02228902	PHASE4	COMPLETED	Iron Absorption Trial
NCT02243735	PHASE4	UNKNOWN	Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia
NCT02271997	PHASE4	COMPLETED	Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass
NCT03295851	PHASE4	UNKNOWN	Preoperative Intravenous Iron Infusion to Reduce Post-surgical Complications: a Pilot Randomised Control Trial
NCT05278793	PHASE4	UNKNOWN	The Efficacy of Intermittent Versus Daily Oral Iron Supplementation in Anaemic Pregnant Women.
NCT05456932	PHASE4	UNKNOWN	Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease
NCT07381426	PHASE3	NOT_YET_RECRUITING	Ferric Citrate in Iron Deficiency Anemia During Pregnancy
NCT01656434	PHASE3	TERMINATED	Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)
NCT03106454	PHASE3	COMPLETED	Ovulation Incidence in Oral Contraceptive Users
NCT03212781	PHASE3	COMPLETED	Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women
NCT04130828	PHASE3	COMPLETED	Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia
NCT01949467	PHASE2	COMPLETED	Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.
NCT02128971	PHASE2	UNKNOWN	A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo
NCT03484845	PHASE1/PHASE2	UNKNOWN	Lactoferrin Versus Ferrous Fumarate for Treatment of Mild to Moderate Iron Deficiency Anemia During Pregnancy
NCT00867867	PHASE1	COMPLETED	Ferrous Fumarate and Ferric Pyrophosphate as Food Fortificants in Developing Countries
NCT01762995	PHASE1	COMPLETED	A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects
NCT04008147	Not specified	RECRUITING	Hepcidin and Glucose Metabolism
NCT06014983	Not specified	RECRUITING	Efficacy and Adverse Side Effects of Two Forms of Iron in Pregnancy
NCT00841061	Not specified	COMPLETED	Cereals as a Source of Iron for Breastfed Infants
NCT02096250	Not specified	COMPLETED	Iron Absorption in Haiti
NCT02346188	Not specified	COMPLETED	Effects of Iron and/or Zinc Supplementation in Mexican School Children Exposed to Lead
NCT02831712	Not specified	UNKNOWN	Effect of Iron Status on Occurrence of Non-transferrin-bound Iron (NTBI) in Serum in Response to an Oral Iron Load
NCT03762148	Not specified	COMPLETED	Determination of a Dose-dependent Effect of GOS on Iron Absorption, and Addition of Vitamin C
NCT03996421	Not specified	COMPLETED	Determination of Iron Absorption Mechanism From Ferrous Fumarate With GOS
NCT04163406	Not specified	COMPLETED	The Effect of Human Milk Oligosaccharides and Galacto-oligosaccharides on Iron Absorption in Kenyan Infants
NCT04194255	Not specified	COMPLETED	The Effect of Different Prebiotics on Iron Absorption From High Dose Iron Supplements
NCT04931641	Not specified	COMPLETED	Potential of Prebiotic Galacto-oligosaccharides in Improving Efficacy and Safety of Oral Iron Supplementation in HIV-infected Children
NCT05033483	Not specified	COMPLETED	Do Iron Supplements Impact the Gut Microbiome of Women of Reproductive Age?
NCT05581420	Not specified	UNKNOWN	Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy.
NCT06303531	Not specified	UNKNOWN	Efficacious Iron for Iron Deficiency Anemia in Adults Aged ≥18 Years

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).